Analysis on clinical safety and efficacy of Reduning Injection combined with Ceftazidime Sodium in treatment for patients with Mycoplasma Pneumoniae pneumonia
PAN Bo1 GAO Jingyu2
1.Teaching Office of Pathogeny Biology, Institute of Medical Laboratory and Technology, Daqing Branch of Harbin Medical University, Heilongjiang Province, Daqing 163319, China;
2.Party Committee Propaganda United Front Department, Daqing Branch of Harbin Medical University, Heilongjiang Province, Daqing 163319, China
Abstract：Objective To analyze the clinical safety and efficacy of Reduning Injection combined with Ceftazidime Sodium in treatment for Mycoplasma Pneumoniae pneumonia. Methods A total of 110 patients from April 2016 to July 2017 treated in the First Affiliated Hospital of Harbin Medical University with Mycoplasma Pneumoniae pneumonia were selected as research objects, and they were randomly divided into experimental group and control group via blind method, with 55 patients in each group. The experimental group was treated by Reduning Injection combined with Ceftazidime Sodium, while the control group was treated by Ceftazidime Sodium. Improvement time of symptoms, serum C-reactive protein (CRP), effective rate and adverse reactions between the two groups were compared. Results The disappearing time of pulmonary moist rales, chest X-ray shadows, fever, cough and wheezing in experimental group were significantly shorten than those in control group, the differences were statistically significant (P ＜ 0.05). The hospitalization time in experimental group was significantly less than that in control group, the difference was statistically significant (P ＜ 0.05). After treatment, the levels of CRP in the two groups were lower than those of the before treatment, and the experimental group was lower than that in control group, the difference was statistically significant (P ＜ 0.05). The total effective rate in experimental group was 96.36%, which was significantly higher than that in control group (83.64%), the difference was statistically significant (P ＜ 0.05). No severe adverse reactions occurred in the two groups. The incidence rate of adverse reactions in experimental group was significantly lower than that in control group, the difference was statistically significant (P ＜ 0.05). Conclusion The effect of Reduning Injection combined with Ceftazidime Sodium in treatment for Mycoplasma Pneumoniae pneumonia is better, that can alleviate the shortterm inflammatory reaction, improve the symptoms, inhibit aggravation of the disease, and reduce adverse reactions. The safety of Reduning Injection combined with Ceftazidime Sodium is good.
潘博1 高靖宇2. 热毒宁注射液联合头孢他啶钠治疗支原体肺炎患者的安全性及可行性[J]. 中国医药导报, 2018, 15(22): 139-142.
PAN Bo1 GAO Jingyu2. Analysis on clinical safety and efficacy of Reduning Injection combined with Ceftazidime Sodium in treatment for patients with Mycoplasma Pneumoniae pneumonia. 中国医药导报, 2018, 15(22): 139-142.
[1] 余丽丽，赵德育.肺炎支原体肺炎发病机制研究进展[J].中国实用儿科杂志，2017，32（3）：234-238.
[2] 殷勇，陆权，闫晓莉.肺炎支原体感染的流行病学[J].中华儿科杂志，2016，54（2）：196-197.
[3] 甄波，胡国斌，曾艳，等.难治性肺炎支原体肺炎患儿血清炎性细胞因子水平变化及意义[J].山东医药，2015，55（44）：73-75.
[4] 张慧芬，白海涛，李基明，等.肺炎支原体肺炎患儿肺炎支原体耐药性与DNA载量和基因型的关系研究[J].中国当代儿科杂志，2017，19（11）：1180-1184.
[5] 葛均波，徐永健.内科学（第8版）[M].人民卫生出版社，2013：49.
[6] 《抗菌药物临床试验技术指导原则》写作组.抗菌药物临床试验技术指导原则[J].中国临床药理学杂志，2014，30（9）：844-856.
[7] 谭梦婷，徐小红，田小华，等.阿奇霉素联合孟鲁司特钠治疗小儿肺炎支原体肺炎的疗效及对血清CRP的影响[J].中国医学工程，2017，25（11）：83-85.
[8] 张新星，陈正荣，顾文婧，等.难治性肺炎支原体肺炎患儿肺泡灌洗液中SB7-H3及细胞因子表达[J].临床儿科杂志，2016，34（8）：561-565.
[9] 曹诗燕.布地奈德联合阿奇霉素序贯疗法对肺炎支原体肺炎患儿细胞免疫及肺功能状态的影响研究[J].中国医药科学，2017，7（15）：20-22，26.
[10] 李永赞，谢悦坚，李磊邦.儿童感染肺炎支原体的C反应蛋白和中性粒白细胞检测的临床意义[J].中国医药科学，2018，8（3）：144-146.
[11] Lozano R，Naghavi M，Foreman K，et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010：a systematic analysis for the global burden of disease study 2010 [J]. Lancet，2013， 381（9867）：628.
[12] Hogan MC，Foreman KJ，Naghavi M，et al. Maternal mortality for 181 countries，1980-2008：a systematic analysis ofprogress towards millennium development goal 5 [J]. Lancet，2010，375（9726）：1609-1623.
[13] Liang J，Dai L，Zhu J，et al. Preventable maternal mortality：geographic/rural-urban differences and associated factors from the population-based Maternal Mortality Surveillance System in China [J]. BMC Public Health，2011，11：243.
[14] Liu Y，Ye XY，Zhang H，et al. Characterization of macroliade resistance in mycoplasma pneumoniae isolate from children in shanghai，China [J]. Diagn Microbiol Infect Dis，2010，67（4）：355-358.
[15] 蔡亲武，杨子江，王昌乐.阿奇霉素治疗小儿上呼吸道肺炎支原体感染临床效果观察[J].河北医学，2018，24（2）：328-332.
[16] 杜峰.头孢他啶钠联合阿奇霉素治疗小儿肺炎支原体肺炎的临床效果及安全性分析[J].中国妇幼保健，2017， 32（7）：1511-1513.
[17] 梁树森，陈媚，黄国坚，等.联用头孢他啶钠与阿奇霉素治疗小儿肺炎支原体肺炎的临床效果及安全性[J].当代医药论丛，2018，16（7）：147-148.
[18] 付佳.头孢他啶钠联合阿奇霉素治疗小儿肺炎支原体肺炎的效果及安全性分析[J].中国卫生标准管理，2018， 9（3）：82-84.
[19] 卢仕仰，黄从付，刘巧红，等.头孢他啶钠联合阿奇霉素治疗小儿肺炎支原体肺炎的临床效果[J].中国当代医药，2016，23（5）：59-60，64.
[20] 寇东灿.头孢他啶联合阿奇霉素治疗小儿急性下呼吸道感染的临床疗效[J].北方药学，2018，15（3）：59.
[21] 刘怡.阿奇霉素治疗急性细菌性下呼吸道感染的有效性和安全性分析[J].中国当代医药，2017，24（2）：128-130.
[22] 田岩，苑波，曲艳平.热毒宁注射液与莫西沙星联合治疗成人肺炎支原体肺炎的临床观察[J].世界最新医学信息文摘，2016，16（54）：89.
[23] 魏尤良.热毒宁与莫西沙星联用对成人肺炎支原体肺炎患者的临床疗效评价[J].抗感染药学，2017，14（6）：1237-1238.
[24] 胡玥.热毒宁注射液的药理作用及抗病毒作用[J].临床合理用药杂志，2016，9（7）：174-176.
2018, Vol. 15 
京公网安备 11010502046598号